Ganciclovir: Brands, Price & Uses in Bangladesh

Established / FDA-approved indications

• Treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with AIDS.
• Prevention of CMV disease in solid organ transplant recipients (e.g., kidney, heart, liver) who are at risk of CMV infection.

Guideline-supported / commonly used off-label uses

• Prevention and pre-emptive treatment of CMV disease in hematopoietic stem cell transplant recipients (per transplant infectious disease guidelines).
• Treatment of other severe CMV end-organ disease (e.g., CMV colitis, CMV pneumonitis, CMV esophagitis) in immunocompromised hosts, usually as part of specialist-directed combination management.
• Congenital CMV infection in neonates with central nervous system involvement (specialist-directed, weight-based dosing; oral valganciclovir is often preferred once feasible).

Ganciclovir is not indicated for the treatment of common, self-limited viral illnesses and should be reserved for confirmed or strongly suspected CMV disease in at-risk patients under specialist supervision.

CMV retinitis (adults, normal renal function)

Prevention of CMV disease in transplant recipients (adults, normal renal function)

Renal impairment (adults)

Dose must be reduced according to creatinine clearance; see the Use in Special Populations section for the detailed renal dose-adjustment table. Adjustment is essential because Ganciclovir is renally cleared and accumulates in renal impairment, increasing toxicity risk.

Administration instructions

• Ganciclovir must be given only by slow intravenous infusion over 1 hour, at a concentration not exceeding recommended limits. Rapid or bolus IV infusion increases toxicity.
• Do NOT administer by intramuscular or subcutaneous injection, as extreme pH will cause severe tissue irritation.
• Adequate hydration should be maintained during infusion.
• Handle reconstituted solution with care (avoid direct skin/eye contact) as Ganciclovir is considered potentially teratogenic and carcinogenic.
• Take/receive exactly as prescribed and administered by a qualified healthcare professional; do not alter the dose, frequency, or duration without medical advice, and complete the full course as directed.

Very common / common

• Hematologic: neutropenia (granulocytopenia), anemia, thrombocytopenia — the most important and frequent toxicities of Ganciclovir (see Precautions and Warnings).
• General: fever, chills, asthenia (weakness), headache.
• Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, decreased appetite.
• Others: elevated liver enzymes, elevated serum creatinine, cough, dyspnea, rash, sweating.

Serious (less common but important)

• Severe bone marrow suppression, including pancytopenia and aplastic anemia.
• Seizures, confusion, and other central nervous system effects.
• Serious skin reactions, including Stevens-Johnson syndrome (rare).
• Renal impairment/renal failure.
• Cardiac arrhythmias (reported rarely).
• Gastrointestinal bleeding or perforation (reported rarely).

Report any unusual bruising, bleeding, signs of infection (fever, sore throat), or severe rash to a physician immediately.